DSS Document Security Systems Inc.

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth

ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc. (NYSE American: IBO) in a strategic, all-equity transaction valued at approximately $1.15 million. This divestiture aligns with DSS’ ongoing strategy to optimize its portfolio and concentrate on core growth areas.

Celios® is a cutting-edge air purification technology featuring a patented three-stage filtration system capable of removing ultrafine particles as small as ten (10) nanometers, helping to improve indoor air quality and mitigate airborne health risks. The sale of this asset allows DSS to focus on other high-impact investments across its diversified business segments.

“The sale of Celios® to Impact BioMedical represents another step in our strategic efforts to streamline our holdings and focus on our core business objectives,” said Jason Grady, CEO of DSS, Inc. “Impact BioMedical is well-positioned to leverage Celios’® innovative air purification technology, and we believe this transition will maximize the platform’s potential while allowing DSS to continue to focus into areas with stronger long-term synergies.”

This transaction strengthens DSS’ commitment to advancing its strategic vision by concentrating on key business verticals that drive long-term shareholder value.

About DSS, Inc.:

DSS, Inc. (NYSE American: DSS) is a multinational company operating businesses across multiple high-growth sectors. DSS focuses on creating, acquiring, and investing in innovative companies that drive sustainable value for its shareholders.

About Celios®:

Celios® is an advanced air purification technology company committed to improving indoor air quality through patented filtration solutions. Designed for efficiency and portability, Celios® systems provide industry-leading air purification that meets the highest standards of cleanliness and safety.

Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that may cause actual results to differ materially from those projected. DSS, Inc. disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contact:

DSS Inc. Investor Relations

Email:

Phone: +1 (585) 565-2422



EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Document Security Systems Inc.

 PRESS RELEASE

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining...

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc. (NYSE American: IBO) in a strategic, all-equity transaction valued at approximately $1.15 million. This divestiture aligns with DSS’ ongoing strategy to optimize its portfolio and concentrate on core growth areas. Celios® is a cutting-edge air purifi...

 PRESS RELEASE

DSS, Inc. Issues Letter to Shareholders

DSS, Inc. Issues Letter to Shareholders NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) a multinational company operating businesses within diversified market sectors that strategically acquires and develops assets to increase shareholder value, today issued the following letter to shareholders: Dear Esteemed Shareholders, I am pleased to provide you with significant updates regarding the leadership of DSS, Inc. and to outline the strategic direction we are pursuing as a Company. It is with great honor that I announce my appointment as Interim Chief Executive...

DSS Inc: 1 director

A director at DSS Inc bought 1,025,746 shares at 0.975USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proud...

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol “IBO,” these shares will b...

 PRESS RELEASE

AmericaFirst Funds Trust Announces Changes to Board of Trustees

AmericaFirst Funds Trust Announces Changes to Board of Trustees NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- AmericaFirst Funds, a subsidiary of DSS, Inc. (NYSE American: DSS), today announced that effective August 9, 2024, David Friedensohn, Monica Himes and Allan Siegel have resigned from their positions as independent directors. The Trust is pleased to announce the election of three new independent directors by shareholder proxy vote: Dr. Prabir Datta, Darryl Robinson and Mark Gronet. These individuals are seasoned senior investment executives who bring a wealth of experience and ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch